Cordyceps Sunshine Biotech Holdings Co., Ltd. revenue by segment RAJAF
Annual
Quarterly
Cordyceps Sunshine Biotech Holdings Co., Ltd. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product Sales at $1.1 million, 86% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
|---|---|---|---|---|
| Revenue |
1
|
1
|
1
|
0
|
| Product Sales |
1
-10.9%
share 85.9%
|
1
+99.6%
share 95.8%
|
1
share 68.2%
|
—
|
| Revenue Related Parties |
0
+231.3%
share 14.1%
|
0
-58.3%
share 4.2%
|
0
share 14.4%
|
—
|
| Training |
—
|
—
|
0
share 17.5%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- RAJAF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885680
- Former names
- Cordyceps Sunshine Biotech Holdings Co., Ltd. (until Jun 25, 2026)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
- Aurora Cannabis Inc ACB
Source: SEC EDGAR filings. This is company-reported data, not investment advice.